Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test
The protective effects of deflazacort against the inflammation that follows the conjunctival provocation test (CPT) by specific allergen were assessed in 24 patients with rhinoconjunctivitis caused by Parietaria judaica in a double‐blind study. After a screening CPT, patients were randomized into fo...
Gespeichert in:
| Veröffentlicht in: | Allergy (Copenhagen) 1993-08, Vol.48 (6), p.421-430 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 430 |
|---|---|
| container_issue | 6 |
| container_start_page | 421 |
| container_title | Allergy (Copenhagen) |
| container_volume | 48 |
| creator | Ciprandi, G. Buscaglia, S. Pesce, G. P. Iudice, A. Bagnasco, M. Canonica, G. W. |
| description | The protective effects of deflazacort against the inflammation that follows the conjunctival provocation test (CPT) by specific allergen were assessed in 24 patients with rhinoconjunctivitis caused by Parietaria judaica in a double‐blind study. After a screening CPT, patients were randomized into four treatment groups, each being given deflazacort (oral tablets) at 6, 30, and 60 mg once daily, or matching placebo, for 3 d, outside the pollen season. Clinical evaluation (itching, hyperemia, lacrimation, and swelling of eyelids) and cytologic assessment (number of inflammatory cells in conjunctival scraping and evaluation of ICAM (intercellular adhesion molecule)‐1/CD54 expression on epithelial cells) were performed at base line, 30 min (early‐phase reaction (EPR), 6 h and 24 h (late‐phase reaction (LPR)) after specific CPT, and before and after treatment. Neither the EPR clinical reactions nor the EPR total number of inflammatory cells was modified by deflazacort. However, the LPR clinical effects were significantly reduced by deflazacort at 30 or 60mg/d (P |
| doi_str_mv | 10.1111/j.1398-9995.1993.tb00740.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76079004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76079004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4261-bb355b1d98f58b3522478ebf6b3e730e5614b6d294e74923d4fe1ef2a38825553</originalsourceid><addsrcrecordid>eNqVkc1u1DAUhS1EVaY_j4BkdcEuqX-TuAukqkBBGqkbWFu2c9Nm5EkG2ykdVqy74hn7JHU0o9kivLHlc849lj-ELigpaV6Xq5Jy1RRKKVlSpXiZLCG1IOXTG7Q4SG_RglAiCyF58w6dxLgi2cUUOUbHtSKMMLpAz5-g8-a3cWNIeBPGBC5FbO5NP8SEvUnw8ufv5sFEwHZKeBgTBhP89nAbwLjUj0PE_dBODlpstzg9ADbeQ7iHITvjBlzf9Q67cVhNQ_Y_Gj-3PY7OzGGcIKYzdNQZH-F8v5-iH18-f7_5Wizvbr_dXC8LJ1hFC2u5lJa2qulkk8-MiboB21WWQ80JyIoKW7VMCaiFYrwVHVDomOFNw6SU_BR92M3ND_g55WK97qMD780A4xR1XZH8PUT800irupIV59l4tTO6MMYYoNOb0K9N2GpK9ExMr_SMRc9Y9ExM74nppxx-v2-Z7BraQ3SPKOsfd_qv3sP2Pybr6-VS5AGvwMmsMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16765633</pqid></control><display><type>article</type><title>Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ciprandi, G. ; Buscaglia, S. ; Pesce, G. P. ; Iudice, A. ; Bagnasco, M. ; Canonica, G. W.</creator><creatorcontrib>Ciprandi, G. ; Buscaglia, S. ; Pesce, G. P. ; Iudice, A. ; Bagnasco, M. ; Canonica, G. W.</creatorcontrib><description>The protective effects of deflazacort against the inflammation that follows the conjunctival provocation test (CPT) by specific allergen were assessed in 24 patients with rhinoconjunctivitis caused by Parietaria judaica in a double‐blind study. After a screening CPT, patients were randomized into four treatment groups, each being given deflazacort (oral tablets) at 6, 30, and 60 mg once daily, or matching placebo, for 3 d, outside the pollen season. Clinical evaluation (itching, hyperemia, lacrimation, and swelling of eyelids) and cytologic assessment (number of inflammatory cells in conjunctival scraping and evaluation of ICAM (intercellular adhesion molecule)‐1/CD54 expression on epithelial cells) were performed at base line, 30 min (early‐phase reaction (EPR), 6 h and 24 h (late‐phase reaction (LPR)) after specific CPT, and before and after treatment. Neither the EPR clinical reactions nor the EPR total number of inflammatory cells was modified by deflazacort. However, the LPR clinical effects were significantly reduced by deflazacort at 30 or 60mg/d (P<0.01), as compared with placebo. The total number of inflammatory cells during LPR was significantly reduced by deflazacort at 30 or 60 nig/d ((P<0.01), as compared with placebo. Furthermore, CD54 expression was significantly reduced by deflazacort at 30 or 60 mg/d both in the EPR ((P<0.01) and LPR ((P<0.01), as compared with placebo. None of the studied indicators were modified at the 6 mg/d dose. This study shows that deflazacort has a highly protective action against clinical and cellular LPR effects induced by the specific CPT, In addition, deflazacort markedly reduces CD54 expression on the conjunctival epithelium during both EPR and LPR.</description><identifier>ISSN: 0105-4538</identifier><identifier>EISSN: 1398-9995</identifier><identifier>DOI: 10.1111/j.1398-9995.1993.tb00740.x</identifier><identifier>PMID: 7902021</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Allergens - administration & dosage ; Allergens - adverse effects ; Anti-Inflammatory Agents - therapeutic use ; Antigens, CD - biosynthesis ; CD54 (ICAM‐I (intercellular adhesion molecule‐1) ; Cell Adhesion Molecules - biosynthesis ; conjunctival provocation test ; Conjunctivitis, Allergic - complications ; Conjunctivitis, Allergic - immunology ; Conjunctivitis, Allergic - pathology ; Conjunctivitis, Allergic - prevention & control ; deflazacort ; Double-Blind Method ; early‐phase reaction ; Epithelium - metabolism ; Epithelium - pathology ; Female ; Humans ; inflammatory response ; Intercellular Adhesion Molecule-1 ; late‐phase reaction ; Male ; Middle Aged ; Parietaria judaica ; Pregnenediones - therapeutic use ; Rhinitis, Allergic, Perennial - complications ; Rhinitis, Allergic, Perennial - immunology ; Rhinitis, Allergic, Perennial - pathology ; Rhinitis, Allergic, Perennial - prevention & control ; Time Factors</subject><ispartof>Allergy (Copenhagen), 1993-08, Vol.48 (6), p.421-430</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4261-bb355b1d98f58b3522478ebf6b3e730e5614b6d294e74923d4fe1ef2a38825553</citedby><cites>FETCH-LOGICAL-c4261-bb355b1d98f58b3522478ebf6b3e730e5614b6d294e74923d4fe1ef2a38825553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1398-9995.1993.tb00740.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1398-9995.1993.tb00740.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7902021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ciprandi, G.</creatorcontrib><creatorcontrib>Buscaglia, S.</creatorcontrib><creatorcontrib>Pesce, G. P.</creatorcontrib><creatorcontrib>Iudice, A.</creatorcontrib><creatorcontrib>Bagnasco, M.</creatorcontrib><creatorcontrib>Canonica, G. W.</creatorcontrib><title>Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test</title><title>Allergy (Copenhagen)</title><addtitle>Allergy</addtitle><description>The protective effects of deflazacort against the inflammation that follows the conjunctival provocation test (CPT) by specific allergen were assessed in 24 patients with rhinoconjunctivitis caused by Parietaria judaica in a double‐blind study. After a screening CPT, patients were randomized into four treatment groups, each being given deflazacort (oral tablets) at 6, 30, and 60 mg once daily, or matching placebo, for 3 d, outside the pollen season. Clinical evaluation (itching, hyperemia, lacrimation, and swelling of eyelids) and cytologic assessment (number of inflammatory cells in conjunctival scraping and evaluation of ICAM (intercellular adhesion molecule)‐1/CD54 expression on epithelial cells) were performed at base line, 30 min (early‐phase reaction (EPR), 6 h and 24 h (late‐phase reaction (LPR)) after specific CPT, and before and after treatment. Neither the EPR clinical reactions nor the EPR total number of inflammatory cells was modified by deflazacort. However, the LPR clinical effects were significantly reduced by deflazacort at 30 or 60mg/d (P<0.01), as compared with placebo. The total number of inflammatory cells during LPR was significantly reduced by deflazacort at 30 or 60 nig/d ((P<0.01), as compared with placebo. Furthermore, CD54 expression was significantly reduced by deflazacort at 30 or 60 mg/d both in the EPR ((P<0.01) and LPR ((P<0.01), as compared with placebo. None of the studied indicators were modified at the 6 mg/d dose. This study shows that deflazacort has a highly protective action against clinical and cellular LPR effects induced by the specific CPT, In addition, deflazacort markedly reduces CD54 expression on the conjunctival epithelium during both EPR and LPR.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Allergens - administration & dosage</subject><subject>Allergens - adverse effects</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antigens, CD - biosynthesis</subject><subject>CD54 (ICAM‐I (intercellular adhesion molecule‐1)</subject><subject>Cell Adhesion Molecules - biosynthesis</subject><subject>conjunctival provocation test</subject><subject>Conjunctivitis, Allergic - complications</subject><subject>Conjunctivitis, Allergic - immunology</subject><subject>Conjunctivitis, Allergic - pathology</subject><subject>Conjunctivitis, Allergic - prevention & control</subject><subject>deflazacort</subject><subject>Double-Blind Method</subject><subject>early‐phase reaction</subject><subject>Epithelium - metabolism</subject><subject>Epithelium - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>inflammatory response</subject><subject>Intercellular Adhesion Molecule-1</subject><subject>late‐phase reaction</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parietaria judaica</subject><subject>Pregnenediones - therapeutic use</subject><subject>Rhinitis, Allergic, Perennial - complications</subject><subject>Rhinitis, Allergic, Perennial - immunology</subject><subject>Rhinitis, Allergic, Perennial - pathology</subject><subject>Rhinitis, Allergic, Perennial - prevention & control</subject><subject>Time Factors</subject><issn>0105-4538</issn><issn>1398-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkc1u1DAUhS1EVaY_j4BkdcEuqX-TuAukqkBBGqkbWFu2c9Nm5EkG2ykdVqy74hn7JHU0o9kivLHlc849lj-ELigpaV6Xq5Jy1RRKKVlSpXiZLCG1IOXTG7Q4SG_RglAiCyF58w6dxLgi2cUUOUbHtSKMMLpAz5-g8-a3cWNIeBPGBC5FbO5NP8SEvUnw8ufv5sFEwHZKeBgTBhP89nAbwLjUj0PE_dBODlpstzg9ADbeQ7iHITvjBlzf9Q67cVhNQ_Y_Gj-3PY7OzGGcIKYzdNQZH-F8v5-iH18-f7_5Wizvbr_dXC8LJ1hFC2u5lJa2qulkk8-MiboB21WWQ80JyIoKW7VMCaiFYrwVHVDomOFNw6SU_BR92M3ND_g55WK97qMD780A4xR1XZH8PUT800irupIV59l4tTO6MMYYoNOb0K9N2GpK9ExMr_SMRc9Y9ExM74nppxx-v2-Z7BraQ3SPKOsfd_qv3sP2Pybr6-VS5AGvwMmsMg</recordid><startdate>199308</startdate><enddate>199308</enddate><creator>Ciprandi, G.</creator><creator>Buscaglia, S.</creator><creator>Pesce, G. P.</creator><creator>Iudice, A.</creator><creator>Bagnasco, M.</creator><creator>Canonica, G. W.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199308</creationdate><title>Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test</title><author>Ciprandi, G. ; Buscaglia, S. ; Pesce, G. P. ; Iudice, A. ; Bagnasco, M. ; Canonica, G. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4261-bb355b1d98f58b3522478ebf6b3e730e5614b6d294e74923d4fe1ef2a38825553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Allergens - administration & dosage</topic><topic>Allergens - adverse effects</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antigens, CD - biosynthesis</topic><topic>CD54 (ICAM‐I (intercellular adhesion molecule‐1)</topic><topic>Cell Adhesion Molecules - biosynthesis</topic><topic>conjunctival provocation test</topic><topic>Conjunctivitis, Allergic - complications</topic><topic>Conjunctivitis, Allergic - immunology</topic><topic>Conjunctivitis, Allergic - pathology</topic><topic>Conjunctivitis, Allergic - prevention & control</topic><topic>deflazacort</topic><topic>Double-Blind Method</topic><topic>early‐phase reaction</topic><topic>Epithelium - metabolism</topic><topic>Epithelium - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>inflammatory response</topic><topic>Intercellular Adhesion Molecule-1</topic><topic>late‐phase reaction</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parietaria judaica</topic><topic>Pregnenediones - therapeutic use</topic><topic>Rhinitis, Allergic, Perennial - complications</topic><topic>Rhinitis, Allergic, Perennial - immunology</topic><topic>Rhinitis, Allergic, Perennial - pathology</topic><topic>Rhinitis, Allergic, Perennial - prevention & control</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ciprandi, G.</creatorcontrib><creatorcontrib>Buscaglia, S.</creatorcontrib><creatorcontrib>Pesce, G. P.</creatorcontrib><creatorcontrib>Iudice, A.</creatorcontrib><creatorcontrib>Bagnasco, M.</creatorcontrib><creatorcontrib>Canonica, G. W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Allergy (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ciprandi, G.</au><au>Buscaglia, S.</au><au>Pesce, G. P.</au><au>Iudice, A.</au><au>Bagnasco, M.</au><au>Canonica, G. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test</atitle><jtitle>Allergy (Copenhagen)</jtitle><addtitle>Allergy</addtitle><date>1993-08</date><risdate>1993</risdate><volume>48</volume><issue>6</issue><spage>421</spage><epage>430</epage><pages>421-430</pages><issn>0105-4538</issn><eissn>1398-9995</eissn><abstract>The protective effects of deflazacort against the inflammation that follows the conjunctival provocation test (CPT) by specific allergen were assessed in 24 patients with rhinoconjunctivitis caused by Parietaria judaica in a double‐blind study. After a screening CPT, patients were randomized into four treatment groups, each being given deflazacort (oral tablets) at 6, 30, and 60 mg once daily, or matching placebo, for 3 d, outside the pollen season. Clinical evaluation (itching, hyperemia, lacrimation, and swelling of eyelids) and cytologic assessment (number of inflammatory cells in conjunctival scraping and evaluation of ICAM (intercellular adhesion molecule)‐1/CD54 expression on epithelial cells) were performed at base line, 30 min (early‐phase reaction (EPR), 6 h and 24 h (late‐phase reaction (LPR)) after specific CPT, and before and after treatment. Neither the EPR clinical reactions nor the EPR total number of inflammatory cells was modified by deflazacort. However, the LPR clinical effects were significantly reduced by deflazacort at 30 or 60mg/d (P<0.01), as compared with placebo. The total number of inflammatory cells during LPR was significantly reduced by deflazacort at 30 or 60 nig/d ((P<0.01), as compared with placebo. Furthermore, CD54 expression was significantly reduced by deflazacort at 30 or 60 mg/d both in the EPR ((P<0.01) and LPR ((P<0.01), as compared with placebo. None of the studied indicators were modified at the 6 mg/d dose. This study shows that deflazacort has a highly protective action against clinical and cellular LPR effects induced by the specific CPT, In addition, deflazacort markedly reduces CD54 expression on the conjunctival epithelium during both EPR and LPR.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>7902021</pmid><doi>10.1111/j.1398-9995.1993.tb00740.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0105-4538 |
| ispartof | Allergy (Copenhagen), 1993-08, Vol.48 (6), p.421-430 |
| issn | 0105-4538 1398-9995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76079004 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Allergens - administration & dosage Allergens - adverse effects Anti-Inflammatory Agents - therapeutic use Antigens, CD - biosynthesis CD54 (ICAM‐I (intercellular adhesion molecule‐1) Cell Adhesion Molecules - biosynthesis conjunctival provocation test Conjunctivitis, Allergic - complications Conjunctivitis, Allergic - immunology Conjunctivitis, Allergic - pathology Conjunctivitis, Allergic - prevention & control deflazacort Double-Blind Method early‐phase reaction Epithelium - metabolism Epithelium - pathology Female Humans inflammatory response Intercellular Adhesion Molecule-1 late‐phase reaction Male Middle Aged Parietaria judaica Pregnenediones - therapeutic use Rhinitis, Allergic, Perennial - complications Rhinitis, Allergic, Perennial - immunology Rhinitis, Allergic, Perennial - pathology Rhinitis, Allergic, Perennial - prevention & control Time Factors |
| title | Deflazacort protects against late‐phase but not early‐phase reactions induced by the allergen‐specific conjunctival provocation test |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T04%3A06%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deflazacort%20protects%20against%20late%E2%80%90phase%20but%20not%20early%E2%80%90phase%20reactions%20induced%20by%20the%20allergen%E2%80%90specific%20conjunctival%20provocation%20test&rft.jtitle=Allergy%20(Copenhagen)&rft.au=Ciprandi,%20G.&rft.date=1993-08&rft.volume=48&rft.issue=6&rft.spage=421&rft.epage=430&rft.pages=421-430&rft.issn=0105-4538&rft.eissn=1398-9995&rft_id=info:doi/10.1111/j.1398-9995.1993.tb00740.x&rft_dat=%3Cproquest_cross%3E76079004%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16765633&rft_id=info:pmid/7902021&rfr_iscdi=true |